Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.97 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.97 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | DHODH | Q02127 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1796445 | 1.00 | CYP4A11 (0.97) | CYP4A11CYP4F2POLBLOXL2DHODH | |
| SCHEMBL2653147 | 1.00 | CYP4A11 (0.97) | CYP4A11CYP4F2POLBLOXL2DHODH | |
| SCHEMBL2654656 | 1.00 | CYP4A11 (0.97) | CYP4A11CYP4F2POLBLOXL2DHODH | |
| SCHEMBL1628660 | 0.98 | CYP4A11 (1.00) | CYP4A11CYP4F2POLBLOXL2DHODH | |
| SCHEMBL2654777 | 0.93 | CYP4A11 (1.00) | CYP4A11CYP4F2POLBLOXL2DHODH | |
| 1,4-Butanediol SCHEMBL2722579 | 0.87 | CYP4A11 (0.79) | CYP4A11CYP4F2POLBLOXL2ALDH1A1 | |
| SCHEMBL6069166 | 0.86 | CYP4A11 (0.73) | CYP4A11CYP4F2ALDH1A1MAPT | |
| SCHEMBL12814607 | 0.86 | CYP4A11 (0.73) | CYP4A11CYP4F2ALDH1A1MAPT | |
| SCHEMBL10610263 | 0.86 | CYP4A11 (0.73) | CYP4A11CYP4F2LOXL2ALDH1A1TP53 | |
| SCHEMBL14660877 | 0.86 | CYP4A11 (0.73) | CYP4A11CYP4F2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692061-A1 | LOW-MOLECULAR-WEIGHT COMPOUND HAVING CEREBLON-BINDING ACTIVITY, AND USE THEREOF | Aevis Bio, Inc. (KR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| EP-4499628-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024205319-A1 | LOW-MOLECULAR-WEIGHT COMPOUND HAVING CEREBLON-BINDING ACTIVITY, AND USE THEREOF | 주식회사 아이비스바이오 | 2024-10-03 | — | — | WO | disclosed |
| WO-2023180388-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20230091810-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2023-03-23 | — | — | US | disclosed |
| US-11384084-B2 | First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210047332-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY | 2021-02-18 | — | — | US | disclosed |
| WO-2019046612-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| EP-0314280-B1 | Process for the preparation of fused pyridine compounds | UNIV PRINCETON (US) | 1996-02-21 | — | — | EP | disclosed |
| US-5473071-A | Process for the preparation of fused pyridine compounds | TRUSTEES OF PRINCETON UNIVERSITY (US) | 1995-12-05 | — | — | US | disclosed |
| EP-0325343-B1 | L-glutamic acid derivatives | UNIV PRINCETON (US) | 1994-06-22 | — | — | EP | disclosed |
| US-4895946-A | Process for the preparation of fused pyridine compounds | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1990-01-23 | — | — | US | disclosed |
| US-4871743-A | L-glutamic acid derivatives | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0325343-A2 | L-glutamic acid derivatives | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1989-07-26 | — | — | EP | disclosed |
| EP-0314280-A2 | Process for the preparation of fused pyridine compounds | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047332-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | MTHFD1, SHMT1, SHMT2 | CYP4A11 799/4885CYP4F2 39/4885POLB 2172/4885 |
| US-11384084-B2 | First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents | MTHFD1, SHMT1, SHMT2 | CYP4A11 799/4885CYP4F2 39/4885POLB 2172/4885 |
| US-20230091810-A1 | FIRST-IN-CLASS OF SHMT2 AND MTHFD2 INHIBITORS AS ANTITUMOR AGENTS | MTHFD1, SHMT1, SHMT2 | CYP4A11 816/4885CYP4F2 37/4885POLB 2204/4885 |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | CRBN, AR, GNRHR | CYP4A11 419/4885CYP4F2 3023/4885POLB 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.